CR Double-Crane(SH:600062) Ge Long Hui A P P·2025-09-16 08:54Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for its sodium chloride injection of tirofiban hydrochloride, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The wholly-owned subsidiary Anhui Double Crane Pharmaceutical Co., Ltd. is responsible for the newly approved drug [1] - The drug is indicated for adult patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) who experience chest pain within 12 hours and have ECG changes and/or elevated myocardial enzymes [1] - The drug is also used for patients with ST-segment elevation myocardial infarction (STEMI) undergoing planned direct percutaneous coronary intervention (PCI) to reduce the occurrence of major cardiovascular events [1]